Evoke Pharma Inc financial data

Symbol
EVOK on Nasdaq
Location
420 Stevens Avenue, Suite 230, Solana Beach, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 13, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 145 % +21%
Quick Ratio 4.96 % -10.9%
Debt-to-equity 218 % -54%
Return On Equity -101 % +68.6%
Return On Assets -31.9 % +43.3%
Operating Margin -36 % +47.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1.72M shares +15.9%
Common Stock, Shares, Outstanding 1.72M shares +92.5%
Entity Public Float 4.6M USD -13.2%
Common Stock, Value, Issued 172 USD +93.3%
Weighted Average Number of Shares Outstanding, Basic 2.56M shares +82.7%
Weighted Average Number of Shares Outstanding, Diluted 2.56M shares +82.7%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 14.4M USD +67.4%
Operating Income (Loss) -5.19M USD +12%
Nonoperating Income (Expense) -312K USD +14.7%
Net Income (Loss) Attributable to Parent -5.23M USD +18.8%
Earnings Per Share, Basic 0 USD/shares +97.7%
Earnings Per Share, Diluted 0 USD/shares +97.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 11.6M USD +2.09%
Accounts Receivable, after Allowance for Credit Loss, Current 1.23M USD
Inventory, Net 600K USD +21.6%
Other Assets, Current 33.7K USD -7.45%
Assets, Current 15.5M USD +10.7%
Operating Lease, Right-of-Use Asset 107K USD
Other Assets, Noncurrent 6.31K USD
Assets 15.6M USD +10.6%
Employee-related Liabilities, Current 771K USD +30.5%
Liabilities, Current 12.2M USD +25.3%
Operating Lease, Liability, Noncurrent 46.4K USD
Liabilities 12.3M USD +25.8%
Retained Earnings (Accumulated Deficit) -133M USD -4.1%
Stockholders' Equity Attributable to Parent 3.36M USD -23.4%
Liabilities and Equity 15.6M USD +10.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -998K USD +61.3%
Net Cash Provided by (Used in) Financing Activities 25K USD -99.7%
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 1.72M shares +92.5%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -973K USD -120%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 11.6M USD +2.09%
Deferred Tax Assets, Valuation Allowance 28.2M USD -2.45%
Deferred Tax Assets, Gross 28.3M USD -2.33%
Operating Lease, Liability 112K USD
Lessee, Operating Lease, Liability, to be Paid 121K USD
Operating Lease, Liability, Current 66K USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 20.6K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 80.2K USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 8.17K USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 20.6K USD
Deferred Tax Assets, Operating Loss Carryforwards 25M USD +5.08%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 3.27M USD 0%
Operating Lease, Payments 70.8K USD -14.6%
Preferred Stock, Shares Outstanding 0 shares
Interest Expense 500K USD -0.27%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%